Asset
Rondecabtagene Autoleucel
Lyell Immunopharma Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07188558 | phase3 | recruiting | 2026-01-12 | 2029-12-01 | Lyell Immunopharma, Inc. | A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy |
| NCT05826535 | phase1_2 | recruiting | 2023-05-09 | 2028-12-31 | Lyell Immunopharma, Inc. | Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma |
FDA applications (0)
This company has no applications containing this asset.